The key project output of the SISAQOL-IMI Consortium include over 140 recommendation statements on the design, analysis, visualization and interpretation of patient-reported outcomes and quality of life endpoints. The recommendations are accessible here:
https://www.sisaqol-imi.org/2025/02/05/sisaqol-imi-launches-final-recommendations/(odnośnik otworzy się w nowym oknie)Other outputs are aimed at supporting the implementation and dissemination of these recommendations include:
-Journal publication for the release of the recommendations with highlights and link to the SISAQOL-IMI recommendations and supporting tools
-Interactive table
-Patient materials including patient checklist
-Glossary (with scientific and plain text versions)
-Guidebook
-Graphical templates
In 2024, the Consortium finalized all recommendations, and the supporting tools are also nearly final. The journal paper titled “SISAQOL-IMI consensus-based guidelines to design, analyse, interpret and present patient-reported outcomes in cancer clinical trials” has been drafted and approved by the SISAQOL-IMI publication review committee and is planned to be submitted to the Lancet Oncology within February 2025. The guidebook, graphical templates, interactive table and glossary are finalized in terms of content. The software for the interactive tool is being tested and will be finalized before submission of the journal paper.
The SISAQOL-IMI website was updated in 2024 to reflect the updates and to highlight the project outputs. The updated website is live, but supporting tools will be available only after the publication of the journal paper which is expected in the first or second quarter of 2025.
To disseminate and raise interest across different stakeholders, the Consortium organized a public launch event on 4 February 2025 to present highlights of the recommendations and to discuss how different stakeholders can implement them in their work. In this context, a panel discussion was organized with the involvement of representatives from regulatory and HTA agencies, industry, patient organizations, academic clinical trialists, and clinicians.
More than 130 people joined the SISAQOL-IMI public launch event from various organizations majority of which were from pharmaceutical industry. The executive summary and more information on the meeting can be found here:
https://www.sisaqol-imi.org/2025/02/05/sisaqol-imi-launches-final-recommendations/(odnośnik otworzy się w nowym oknie)
